Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study
Not Applicable
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000024180
- Lead Sponsor
- Hamamatsu University School of Medicine, Department of Psychiatry
- Brief Summary
The schizophrenia group showed an increase in the binding potential of MeQAA in the whole brain compared to the healthy group. On the other hand, the binding potential of DPA713 was not significantly different between the two groups. In the future, we plan to conduct a correlation analysis of the binding potential of MeQAA with symptom severity and the binding potential of DPA713, as well as an ROI analysis by defining regions of interest, and submit the results to an international journal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
- With past or current history of serious medical illness and/or brain organic diseases - History of alcoholics or substance abuse or addiction - In pregnancy - No family support
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The binding potential of both 11C-DPA713 and 11C-MeQAA in hippocampus and prefrontal cortex
- Secondary Outcome Measures
Name Time Method cognitive function test (Cog state, TMT, stroop, VFT) Positive and Negative Symptom Scale (PANSS) brain MRI